Department of Health and Human Services June 23, 2011 – Federal Register Recent Federal Regulation Documents
Results 1 - 17 of 17
Guidelines for Determining Probability of Causation Under the Energy Employees Occupational Illness Compensation Program Act of 2000; Revision of Guidelines on Non-Radiogenic Cancers; Extension of Comment Period
On March 21, 2011, the Department of Health and Human Services (HHS) published a Notice of Proposed Rulemaking proposing to treat chronic lymphocytic leukemia (CLL) as a radiogenic cancer under the Energy Employees Occupations Illness Compensation Program Act (EEOICPA) of 2000. The public comment period was scheduled to end on June 20, 2011. We have received a request asking to extend the public comment period. In consideration of this request, HHS is extending the public comment period by 30 days to July 20, 2011.
Determination of Regulatory Review Period for Purposes of Patent Extension; DEXILANT
The Food and Drug Administration (FDA) has determined the regulatory review period for DEXILANT (previously KAPIDEX) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.
Determination of Regulatory Review Period for Purposes of Patent Extension; BROVANA
The Food and Drug Administration (FDA) has determined the regulatory review period for BROVANA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.
Determination of Regulatory Review Period for Purposes of Patent Extension; Fusilev, Levoleucovorin
The Food and Drug Administration (FDA) has determined the regulatory review period for Fusilev (Levoleucovorin) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.
Announcement of Availability of the Report on Carcinogens, Twelfth Edition
The Department of Health and Human Services released the 12th RoC to the public on June 10, 2011. The report is available on the RoC Web site at: https://ntp.niehs.nih.gov/go/roc12 or in printed text or electronically from the Office of the RoC (see ADDRESSES below).
Meeting of the National Toxicology Program (NTP) Board of Scientific Counselors (BSC): Notice of Cancellation
The NTP BSC meeting, scheduled for July 21, 2011, and announced in the Federal Register (76 FR 28785), has been cancelled.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
